These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29707124)

  • 41. Interferon-γ signaling is associated with
    Cardenas H; Jiang G; Thomes Pepin J; Parker JB; Condello S; Nephew KP; Nakshatri H; Chakravarti D; Liu Y; Matei D
    NPJ Precis Oncol; 2019; 3():32. PubMed ID: 31840082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor necrosis factor receptor modulator spermatogenesis-associated protein 2 is a novel predictor of outcome in ovarian cancer.
    Wieser V; Tsibulak I; Degasper C; Welponer H; Leitner K; Parson W; Zeimet AG; Marth C; Fiegl H
    Cancer Sci; 2019 Mar; 110(3):1117-1126. PubMed ID: 30697874
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
    Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
    Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Associations between DNA Damage and PD-L1 Expression in Ovarian Cancer, a Potential Biomarker for Clinical Response.
    Mann EK; Lee KJ; Chen D; da Silva LM; Dal Zotto VL; Scalici J; Gassman NR
    Biology (Basel); 2021 Apr; 10(5):. PubMed ID: 33946684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IFNγ-Induced Bcl3, PD-L1 and IL-8 Signaling in Ovarian Cancer: Mechanisms and Clinical Significance.
    Reddy SU; Sadia FZ; Vancura A; Vancurova I
    Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123403
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemokine Network and Overall Survival in
    Ignacio RMC; Lee ES; Wilson AJ; Beeghly-Fadiel A; Whalen MM; Son DS
    Immune Netw; 2018 Aug; 18(4):e29. PubMed ID: 30181917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Elevated expression of Tweety homologue 3 predicts poor clinical outcomes in ovarian cancer.
    Zhou J; Xu Y; Chen X; Chen F; Zhang J; Zhu X
    J Cancer; 2021; 12(23):7147-7157. PubMed ID: 34729116
    [No Abstract]   [Full Text] [Related]  

  • 48. Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications.
    Romero I; Leskelä S; Mies BP; Velasco AP; Palacios J
    EJC Suppl; 2020 Aug; 15():1-15. PubMed ID: 33240438
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients.
    Pawłowska A; Suszczyk D; Tarkowski R; Paduch R; Kotarski J; Wertel I
    Cancer Manag Res; 2020; 12():9691-9709. PubMed ID: 33116828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development.
    Xiao X; Zeng S; Li Y; Li L; Zhang J
    J Oncol; 2022; 2022():4664651. PubMed ID: 35392432
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors.
    Prieto-Potin I; Idrovo F; Suárez-Gauthier A; Díaz-Blázquez M; Astilleros-Blanco de Córdova L; Chamizo C; Zazo S; Carvajal N; López-Sánchez A; Pérez-Buira S; Aúz-Alexandre CL; Manso R; Plaza-Sánchez J; de Lucas-López V; Pérez-González N; Martín-Valle S; Cristóbal I; Casado V; García-Foncillas J; Rojo F
    Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer.
    Liu W; Wang Y; Xie Y; Dai T; Fan M; Li C; Zou Y
    Cell Death Discov; 2021 Jun; 7(1):136. PubMed ID: 34091590
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
    Dai Y; Sun C; Feng Y; Jia Q; Zhu B
    J Cell Mol Med; 2018 Aug; 22(8):3979-3986. PubMed ID: 29855141
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spatial tumor immune microenvironment phenotypes in ovarian cancer.
    Mateiou C; Lokhande L; Diep LH; Knulst M; Carlsson E; Ek S; Sundfeldt K; Gerdtsson A
    NPJ Precis Oncol; 2024 Jul; 8(1):148. PubMed ID: 39026018
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Insight updating of the molecular hallmarks in ovarian carcinoma.
    Mota A; S Oltra S; Moreno-Bueno G
    EJC Suppl; 2020 Aug; 15():16-26. PubMed ID: 33240439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with
    Terzic J; Seipel A; Dubuisson J; Tille JC; Tsantoulis P; Addeo A; Labidi-Galy SI
    Gynecol Oncol Rep; 2020 Aug; 33():100600. PubMed ID: 32613071
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Integrating cell cycle score for precise risk stratification in ovarian cancer.
    Chen L; Gu H; Zhou L; Wu J; Sun C; Han Y
    Front Genet; 2022; 13():958092. PubMed ID: 36061171
    [No Abstract]   [Full Text] [Related]  

  • 58. Dysregulation of Peripheral Blood Mononuclear Cells and Immune-Related Proteins during the Early Post-Operative Immune Response in Ovarian Cancer Patients.
    Ulevicius J; Jasukaitiene A; Bartkeviciene A; Dambrauskas Z; Gulbinas A; Urboniene D; Paskauskas S
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors.
    Jacome Sanz D; Raivola J; Karvonen H; Arjama M; Barker H; Murumägi A; Ungureanu D
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cutaneous metastasis of PD-L1 positive ovarian carcinoma.
    Hastings V; McEachron J; Kanis MJ
    Gynecol Oncol Rep; 2020 Aug; 33():100607. PubMed ID: 32671171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.